B7-33 Research Guide

Full name: B7-33 (Relaxin Peptide Analog)

A single-chain peptide analog of the hormone relaxin, researched for its anti-fibrotic and cardiovascular/organ-protective effects. Biohackers track it for potential anti-fibrosis and tissue-remodeling benefits; it remains preclinical.

How B7-33 Works

Selectively activates the relaxin receptor RXFP1 pathway, biasing signaling toward anti-fibrotic effects. It reduces collagen deposition and promotes healthy tissue remodeling in heart, lung, and kidney models without some downsides of full-length relaxin.

Dosing Protocol

• Typical dose: Not established for humans
• Frequency: Research only
• Duration: Research only
• Route: Injection (research)

Reported Benefits

• Anti-fibrotic effects (preclinical)
• Cardiac and organ protection (research)
• Healthy tissue remodeling
• Relaxin-pathway (RXFP1) biased signaling

Potential Side Effects

• Unknown human safety
• No approved human use
• Unproven efficacy in humans

Research Citations

1. B7-33 reduces fibrosis (2016) - The relaxin analog B7-33 reduced fibrosis in heart, lung, and kidney models via biased RXFP1 signaling.

Related Cardiovascular Compounds

• Nattokinase - Full Profile
• Serrapeptase - Full Profile
• CoQ10 - Full Profile
• Omega-3 (EPA/DHA) - Full Profile
• Bergamot Extract - Full Profile
• Telmisartan - Full Profile

View full B7-33 profile with 3D molecule viewer →